VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.

VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q34382986

about

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer Targeting the apoptosis pathway in hematologic malignancies Targeting of T/Tn antigens with a plant lectin to kill human leukemia cells by photochemotherapy.Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells.An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.Heterogeneous nuclear ribonucleoprotein K supports vesicular stomatitis virus replication by regulating cell survival and cellular gene expression Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.Induction of apoptosis by an oleanolic acid derivative in SMMC-7721 human hepatocellular carcinoma cells is associated with mitochondrial dysfunction.Comment on "Complex disruption effect of natural polyphenols on Bcl-2-Bax: molecular dynamics simulation and essential dynamics study" by S. Verma, A. Singh and A. Mishra.

P2860

Q27021839-113F5C5B-7927-4964-8C31-501E0ED05835 Q27024422-17A95DB4-2F68-48C0-A802-678A99D74833 Q33999425-13AAEAD9-1C44-4E4A-9A5A-9B770C3AA9A6 Q34656877-6E3CAB40-CE20-4B74-847F-A317AC004A94 Q35742477-DD394EB8-B151-4736-96E3-79798AA20D29 Q35812675-39FAACBA-3E74-4D66-905B-682F875175FA Q36466583-D1D5DDF6-FF45-4305-98AA-4E7671730DC4 Q36696524-5C7124BA-3B7A-4A70-BEEF-748F1D7328B5 Q36984500-03FA22A2-4C3B-424A-9947-4E105C79CB39 Q37123143-B3A4D692-C177-48F2-99DF-67E566B96D11 Q37316872-7100044D-0ED6-4156-BBA9-964EBE829883 Q38110472-D8B4DAC7-53CF-4762-9FC7-962B8E70ADDA Q39127534-D29FE3F9-F19D-4BA4-89B7-911B9AF3D93C Q39145934-09BAB9F4-D0CE-436F-A556-272C88DCF7BA Q40192795-1C1AAD0C-CD85-4033-9B90-428F01038FB5 Q45324769-9C1BAA39-92D0-49A8-991E-80C89E037263 Q50295737-BC467747-9AC5-4FA8-B5D2-97297F7BED54 Q52654582-142FFC0D-0E98-4906-BA24-55254FF66BBE

P2860

VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q34382986

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

VSV oncolysis in combination w ...... chronic lymphocytic leukemia.

@ast

VSV oncolysis in combination w ...... chronic lymphocytic leukemia.

@en

VSV oncolysis in combination w ...... chronic lymphocytic leukemia.

@nl

type

label

VSV oncolysis in combination w ...... chronic lymphocytic leukemia.

@ast

VSV oncolysis in combination w ...... chronic lymphocytic leukemia.

@en

VSV oncolysis in combination w ...... chronic lymphocytic leukemia.

@nl

prefLabel

VSV oncolysis in combination w ...... chronic lymphocytic leukemia.

@ast

VSV oncolysis in combination w ...... chronic lymphocytic leukemia.

@en

VSV oncolysis in combination w ...... chronic lymphocytic leukemia.

@nl

P1433

Q34382986-7D5FA8B9-E831-4C83-A8FA-E66BE69D9EF6

P1476

Q34382986-02EE5CC5-1955-4DA4-96FB-516B45975F47

P2093

Q34382986-256B55E0-D1AC-44B6-A50E-EE614E154480

Q34382986-53DFE601-A0E4-4B44-B97F-D99CEDDCDF8C

Q34382986-6435A6A1-8F2B-4C46-9525-E2CFBA19E6DA

Q34382986-6902507C-5940-4ABF-85A8-85C7F79121A0

Q34382986-C7C7BD7D-EA55-44A4-86FE-21C390E054C6

Q34382986-F4424D70-42CF-45ED-A124-8B1D17041C24

P2860

Q34382986-0BF53FA5-E58D-4C48-8BBE-2B29F6668CEB

Q34382986-13D8A19E-5D5F-423F-9497-40B8789F9BE3

Q34382986-1459976F-12A5-4443-9F85-A58F2BBFC381

Q34382986-179B7AE2-EDC9-42A7-8363-163E726CF1A4

Q34382986-1B21CD13-AEC4-449B-B1A2-DE4F014823CB

Q34382986-1DAC0CD4-49A1-4528-BFA0-995B878334DF

Q34382986-2100B33D-3D26-4DC5-9CC8-5971D7E9AA7D

Q34382986-31AF6FCC-47EF-4473-9C63-263588F3D5D5

Q34382986-3204A577-C979-416C-A1A3-7122D5D3EC8C

Q34382986-35E4B0BE-FD6E-400E-8A5A-470B2FE414C7

P304

Q34382986-A340ED03-4D51-4805-B616-0C7F0C0088BA

P31

Q34382986-8C424E3E-ADCD-4EB2-8291-C396AA931B6D

P356

Q34382986-BA70FD60-1625-41AC-8400-F5CE5263C06F

P433

Q34382986-1E1CE5B7-293F-4FAB-AF38-5A6DA412EFAC

P478

Q34382986-BD4C88B7-21A1-48B5-818B-1C2ABF7CA395

P50

Q34382986-5463B7B5-011D-48A2-8F1F-97ECC2C55D7E

Q34382986-ACDCA30B-8AA0-4EBD-930E-D261DE2D9188

P577

Q34382986-A7EFD749-FF1B-4573-A373-C1EF118DBC88

P5875

Q34382986-B90A9BB2-E6BE-46D1-9C6E-7E0283B167F8

P698

Q34382986-EF0AEE18-21E4-4789-9FBA-A7E471CD0D0B

P921

Q34382986-38F7E01C-93D8-4786-9759-575FDE464B9E

Q34382986-B8BD6E07-1DD4-4E85-B919-92164619D777

P932

Q34382986-CB246CAC-336C-40F8-8B2E-E4245D59DA7A

P356

P1433

Molecular Therapy

P1476

VSV oncolysis in combination w ...... chronic lymphocytic leukemia.

@en

P2093

April Shamy

http://www.w3.org/2001/XMLSchema#string

John Hiscott

http://www.w3.org/2001/XMLSchema#string

Sara Samuel

http://www.w3.org/2001/XMLSchema#string

Stephanie Oliere

http://www.w3.org/2001/XMLSchema#string

Thi Liên-Anh Nguyên

http://www.w3.org/2001/XMLSchema#string

Vanessa F Tumilasci

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infection

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

BAX activation is initiated at a novel interaction site

B-cell chronic lymphocytic leukemia: a bird of a different feather

BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly

Molecular mechanisms of caspase regulation during apoptosis

Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper.

Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways.

P304

2094-2103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2010.188

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Thi Liên-Anh Nguyên

P577

2010-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46273839

http://www.w3.org/2001/XMLSchema#string

P698

20842105

http://www.w3.org/2001/XMLSchema#string

P921

P932

2997588

http://www.w3.org/2001/XMLSchema#string